European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS

Single-cell map of the composition and evolution of T-cell acute lymphoblastic leukemia

Descrizione del progetto

Evoluzione monocellulare nella leucemia linfoblastica acuta

Come molti tipi di cancro, la leucemia linfoblastica acuta (ALL) mostra eterogeneità genetica, il che potrebbe spiegare alcune risposte incomplete al trattamento. Il progetto scTALLmap, finanziato dall’UE, analizzerà il genoma e il trascrittoma di singole cellule di campioni di pazienti ALL al momento della diagnosi, durante il trattamento e in caso di ricaduta. Questa analisi aiuterà a creare una panoramica completa a livello di singola cellula della leucemia linfoblastica acuta, fornendo informazioni sul meccanismo di ricaduta. I ricercatori useranno l’eterogeneità cellulare e la presenza di sottocloni ad alto rischio al momento della diagnosi per eseguire la stratificazione del rischio dei pazienti. In definitiva, queste informazioni apriranno la strada a trattamenti personalizzati rivolti specificamente ai sottocloni della leucemia aggressiva.

Obiettivo

Spaniards have their daily siesta, Germans like sausages and Belgians love beer. Stereotypes can certainly be misleading, just like judging a cell by its membership to a particular cell type, the so-called population-based analysis. Nowadays we know that tumors are tremendously heterogeneous and, in the era of single-cell sequencing, we have the exquisite opportunity to study each individual cell with unprecedented resolution. Acute lymphoblastic leukemia (ALL), which is the most common cancer in children, shows extensive genetic intratumoral heterogeneity. This heterogeneity might be the underlying reason for an incomplete response to treatment and for the development of relapse. In order to envision its clinical implementation, it is essential to first i) generate a single-cell map and ii) accumulate evidence on how the subclonal composition affects the response to treatment. With this aim, I will build a comprehensive single-cell overview of the composition, development and response to therapy for the aggressive subtype T-cell ALL. I will perform integrative single-cell genome and transcriptome profiling of ex vivo carefully selected pediatric samples at diagnosis, during drug treatment and in case of relapse. This approach will provide realtime temporal information about the sensitivity of each cell type to the therapy and about how relapse can develop. I will use state-of-the-art single-cell technologies to which the host institute has early access. Moreover, I will apply my previous single-cell expertise and bring a unique mix of experimental and computational skills to the lab. The results of scTALLmap, will have significant impact in leukemia by paving the way for improved risk-stratification based on the cellular heterogeneity and the presence of high-risk subclones at diagnosis. Ultimately, it will permit the design of novel and more personalized therapeutic modalities sparing toxicity and targeting the full complement of leukemia subclones.

Coordinatore

VIB VZW
Contribution nette de l'UE
€ 178 320,00
Indirizzo
SUZANNE TASSIERSTRAAT 1
9052 ZWIJNAARDE - GENT
Belgio

Mostra sulla mappa

Regione
Vlaams Gewest Prov. Oost-Vlaanderen Arr. Gent
Tipo di attività
Research Organisations
Collegamenti
Costo totale
€ 178 320,00